Neil Soni, MD
Hospice and Palliative Medicine · Fountain Valley, CANPI 1306054150
Payments from drug & device makers
Across 642 payments — averaging $43.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Abbott$2K
- Boston Scientific$887
- Saluda Medical Americas, Inc.$881
- Amgen$821
- USWM, LLC$808
- plus $8K from 54 others
What the payments were for
- Speaking & faculty fees$12,91347%
- Food & beverage$14,16351%
- Education$420%
- Gifts$5062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$12,413
- QULIPTA$5,313
- PROCLAIM$577
- ZIMHI$506
- Roxybond$500
- Evoke$388
- Proclaim IPG$386
- GENERAL PAIN MANAGEMENT$257
- Protege Family of SCS IPGs$153
- RESTORE$142
- Intracept$141
- ETERNA$122
- RYBELSUS$117
- Proclaim Family of SCS IPGs$115
- Senza Spinal Cord Stimulation System$110
- INTELLIS$101
How this compares
$27,624 in reported general payments places this provider in the 95th percentile of 195 hospice and palliative medicine providers in California.
See all hospice and palliative medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 39 | $109,121 |
| OxycontinOxycodone Hcl | 90 | $89,087 |
| UbrelvyUbrogepant | 59 | $84,689 |
| LucemyraLofexidine Hcl | 19 | $83,068 |
| NucyntaTapentadol Hcl | 25 | $56,705 |
| Xtampza ErOxycodone Myristate | 53 | $46,697 |
| QuliptaAtogepant | 31 | $42,554 |
| MovantikNaloxegol Oxalate | 70 | $33,268 |
| Lidocaine | 163 | $26,372 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 668 | $24,838 |
| BelbucaBuprenorphine Hcl | 26 | $24,491 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $16,800 |
| ZenpepLipase/Protease/Amylase | 38 | $15,815 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 391 | $15,733 |
| BotoxOnabotulinumtoxina | 12 | $15,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor, Lucemyra | $364 | $192,18958 claims |
| AbbVieUbrelvy, Qulipta, Botox | $13,805 | $142,639102 claims |
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Belbuca | $642 | $127,892104 claims |
| Redhill Biopharma Inc.Movantik | $37 | $33,26870 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate | $78 | $16,183201 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 hospice and palliative medicine providers in California.
Other hospice and palliative medicine in Fountain Valley
- John HausdorffMonterey$68K
- Sharon YeeArcadia$44K
- Marietta Abalos-GalitoSan Jose$22K
- Humayon KhanSanta Ana$7K
- Sorin BugaDuarte$5K
- Glenn CarrFresno$5K
- Steven HarrisFoster City$5K
- Christopher PhillipsMurrieta$4K
- William DaleDuarte$3K
- Nehal PatelLaguna Hills$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.